All In Biotech

NDA 020453 · Ani Pharms

Pandel

Hydrocortisone Probutate · Topical

Discontinued

Last checked: Nov 20, 2026Latest source record: Jan 25, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Feb 28, 1997

Approved uses

2

Original approval plus efficacy supplements

Registered trials

566

130 Phase 3, 61 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 25, 2017 Supplement 7 · Efficacy LabelLetter
  • Feb 28, 1997 Original approval · Type 2 - New Active Ingredient
1 products under this application
  • PANDEL · HYDROCORTISONE PROBUTATE 0.1% · CREAM, TOPICAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydrocortisone Probutate" as an intervention, any sponsor and status, largest first.

All 566 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pandel (Hydrocortisone Probutate)

2024 spending

$36K

Beneficiaries

14

31 claims

Per beneficiary

$2,590

$14.62 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$39,760
2024$36,266

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.